Eisai delays Eritoran application; Shire touts rival to Genzyme's Gaucher's drug;

 @FierceBiotech: Genentech looking to hire smart, creative types. Report | Follow @FierceBiotech

 @JohnCFierce: Glad to see reform story can fade now. For a daily grunt like me, it seems to be sucking all the air out of the biotech newsroom. | Follow @JohnCFierce

> Eisai announced today that it's delaying its application for the sepsis drug Eritoran. Eisai release

> Alnylam CEO John Maraganore discusses his company's clinical programs, partnering potential and cash position in an interview with Reuters. Story

> Shire is reporting data the company says proves it's safe for patients to switch to the company's newly-approved drug to treat Gaucher's disease, from a better-known rival produced by Genzyme. Report

> GlaxoSmithKline exercised its option to buy 1.56 million common shares of JCR Pharmaceuticals. Report

And Finally... Scientists have found a new and simple way to identify breast cancer patients who are likely to respond well to treatment with a common class of chemotherapy drugs. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.